Conflict of interest: Nothing to declare.
Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion†
Article first published online: 11 NOV 2010
Copyright © 2010 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 56, Issue 3, pages 467–469, March 2011
How to Cite
Oliveira, J. L., Kumar, R., Khan, S. P., Law, M. E., Erickson-Johnson, M., Oliveira, A. M., Ketterling, R. P. and Dogan, A. (2011), Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion. Pediatr. Blood Cancer, 56: 467–469. doi: 10.1002/pbc.22850
- Issue published online: 10 JAN 2011
- Article first published online: 11 NOV 2010
- Manuscript Accepted: 1 SEP 2010
- Manuscript Received: 2 AUG 2010
- acute bilineal leukemia;
- t(5 ;14), 9q;
Acute bilineal leukemias are rare and are commonly associated with t(9;22) and MLL abnormalities. Herein, we report a pediatric case of bilineal T/myeloid acute leukemia associated with del (9q)(q13q22) and TLX3/BCL11B fusion due to the cryptic t(5;14)(q35;32). FISH studies confirmed the TLX3/BCL11B fusion in both the myeloid and lymphoid blasts, while the 9q deletion was restricted to the lymphoid component. Optimal therapy for such patients remains controversial and it is not clear if they should be treated with ALL or AML-based chemotherapeutic regimens. Our patient has been in extended remission following ALL-based chemotherapy and a matched unrelated cord blood transplant. Pediatr Blood Cancer 2011;56:467–469. © 2010 Wiley-Liss, Inc.